Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Andrew Stephenson, M.D., is the Director for the Center of Urologic Oncology at Cleveland Clinic's Glickman Urological and Kidney Institute and a staff member of the Taussig Cancer Institute.$0$0$0$0His clinical and research focus is the treatment of patients with cancers of prostate, bladder, testis, and kidney. He has published over 100 articles in peer-reviewed journals on issues related to prostate, bladder, kidney and testis cancer, many of which have received international mainstream media attention. He has been invited to speak on these subjects at several major international medical conferences.$0$0$0$0$0Dr. Stephenson is board-certified in urology by the American Board of Urology and the Royal College of Physicians and Surgeons of Canada. He has received several awards from organizations such as the Prostate Cancer Foundation, American Society of Clinical Oncology, and Society of Urologic Oncology. He is listed as one of the Best Doctors in America. He is a past recipient of the Urology Teacher of the Year award from Cleveland Clinic and the Young Investigator Award from the Society of Urologic Oncology. He has also been recorgnized as a Rising Star in Urology by the American Urological Association.$0$0$0$0$0Dr. Stephenson receives grant support for prostate cancer research from the Robert Wood Johnson Foundation, American Cancer Society, and the Urology Care Foundation. His research focus is on improving decision-making for patients and physicians for complex urological cancers. He is on the editorial board for several urology and oncology journals.$0$0$0$0$0Dr. Stephenson has extensive experience in robotic and open surgical procedures for cancers of the prostate, bladder, and kidney. He performs nerve-sparing procedures for prostatectomy, cystectomy, and retroperitoneal lymph node dissection. For patients undergoing cystectomy, he has extensive experience in all forms of urinary diversion/reconstruction.$0
Prostate cancer, bladder cancer, testis cancer, kidney cancer, robotic prostatectomy, robotic cystectomy, urinary diversion
Awards & Honors
$0$02014 - Best Docs, Cleveland Magazine, 2007–2014$0$02014 - Best Doctors in America, 2007–2014$0$02012 - Young Investigator Award, Society of Urologic Oncology$0$02009 - Rising Stars in Urology, American Urological Association Foundation $0$02008 - Urology Teacher of the Year, Cleveland Clinic $0$02006 - Merit Award, American Society of Clinical Oncology $0$02005 - Prostate Cancer Foundation Award, Society of Urologic Oncology $0$02003 - Scholar-In-Training Award, American Association for Cancer Research $0$02003 - Frank McGill Travel Fellowship, McGill University Health Centre Foundation $0$02002 - Post-Resident Research Scholar, American Foundation for Urologic Disease $0$01993 - Phi Beta Kappa, Eta of New York Chapter, Colgate University $0$0
Innovations & Patents
$0$0Development of several nomograms for prostate cancer. These prognostic models provide accurate predictions of treatment outcome for prostate cancer and are widely used for the counseling of patients with localized and advanced prostate cancer. $0$0
$0$0Society of Urologic Oncology $0$0American Urological Association $0$0American Society of Clinical Oncology $0$0American College of Surgeons $0$0Canadian Urological Association $0$0American Board of Urology $0$0
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical education about recent trends. The collaborations are reviewed as part of the Cleveland
Clinic's procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. The Cleveland Clinic requires its doctors to approve the public disclosures of their scientific collaborations with industry. As of 8/31/2014 the review process regarding Dr. Stephenson's disclosure had not been completed. Patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.